Drug Trial Radar · NCT05571943
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
542
Actual
Start
Sep 15, 2022
Primary completion
Jul 31, 2024
Study completion Jul 31, 2024
Sponsor
- Lead sponsor
- Acrotech Biopharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment 1% in subjects ≥2 years of age with mild to moderate AD. The study will also evaluate the long-term efficacy of difamilast ointment 1%, including durability of response.
Conditions
- Atopic Dermatitis
Interventions
DifamilastDrug
Difamilast Ointment 1%
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and their relationship to study drugTime frame: 52 week study period
- Proportion of subjects who discontinue due to an AE over the study periodTime frame: 52-week study period
Locations
63 sites in 1 country. Site status is shown where the registry gives one.
Qualmedica Research, LLC
Birmingham, Alabama
AllerVie Health
Birmingham, Alabama
Elite Clinical Studies, LLC
Phoenix, Arizona
NEA Baptist Clinic-Dermatology
Jonesboro, Arkansas
First OC Dermatology
Fountain Valley, California
Center for Dermatology Clinical Research, Inc.
Fremont, California
Southern CA Dermatology Skin and Laser
Laguna Niguel, California
Antelope Valley Clinical Trials
Lancaster, California
Dermatology Research Associates
Los Angeles, California
Clinical Trials Research Institute
Thousand Oaks, California
Clarity Dermatology, LLC
Castle Rock, Colorado
IMMUNOe Research Centers
Centennial, Colorado
TrueBlue Clinical Research
Brandon, Florida
Annexus Dermatology & Aethestics
DeLand, Florida
Accel Research - Edgewater Clinical Research Unit
Edgewater, Florida
Skin Care Research
Hollywood, Florida
Kirsch Dermatology
Naples, Florida
Tory Sullivan, MD PA
North Miami Beach, Florida
Pure Skin Dermatology & Aesthetics
Orlando, Florida
Nona Pediatrics
Orlando, Florida
Accel Research - Ormond Clinical Research Unit
Ormond Beach, Florida
Olympian Clinical Research
St. Petersburg, Florida
Solaris Clinical Research
Meridian, Idaho
Arlington Dermatology
Rolling Meadows, Illinois
DS Research
Clarksville, Indiana
Qualmedica Research, LLC
Evansville, Indiana
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
The Indiana Clinical Trials Center
Plainfield, Indiana
South Bend Clinic
South Bend, Indiana
Options Research Group, LLC
West Lafayette, Indiana
Meridian Clinical Research
Overland Park, Kansas
Qualmedica Research, LLC
Bowling Green, Kentucky
DS Research
Louisville, Kentucky
Clinical Trials Management, LLC
Covington, Louisiana
Avant Research Associates, LLC
Crowley, Louisiana
Clinical Trials Management, LLC
Metairie, Louisiana
DermAssociates, LLC
Rockville, Maryland
Metro Boston Clinical Partners
Brighton, Massachusetts
Oakland Hills Dermatology, PC
Auburn Hills, Michigan
Michigan Dermatology Institute
Waterford, Michigan
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.